...
首页> 外文期刊>Future oncology >Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers
【24h】

Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers

机译:联合的Ang-2和VEGF血清水平:牵手作为非小细胞肺癌中新的不可或缺的生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Evaluate if serum levels of VEGF and Ang-2 are correlated in non-small-cell lung cancers (NSCLCs) and its implications in the diagnostic and prognostic of the disease. Patients & methods: Unselected cohort of 145 NSCLC patients and 30 control individuals. The serum levels of Ang-2 and VEGF of each patient were measured by ELISA prior to treatment. Results & conclusions: Serum levels of Ang-2 and VEGF are correlated (p < 0.0001). High serum levels of Ang-2 and VEGF isolated and both combined (high(Ang-2/VEGF)) correlate with likelihood of presenting NSCLC (p = 0.016; p = 0.003; p < 0.0001, respectively). Serum levels of Ang-2 and high(Ang-2/VEGF) but not VEGF alone are independent prognostic factors (p = 0.001; p = 0.619; p = 0.005). High(Ang-2/VEGF) serum levels could be exploited as a new valuable integral biomarker in NSCLC.
机译:目的:评估非小细胞肺癌(NSCLCs)中VEGF和Ang-2的血清水平是否相关,及其对疾病诊断和预后的影响。患者和方法:145名非小细胞肺癌患者和30名对照患者的未选队列。在治疗前通过ELISA测量每位患者的血清Ang-2和VEGF水平。结果与结论:血清Ang-2和VEGF水平相关(p <0.0001)。分离的高浓度的Ang-2和VEGF以及二者联合使用(高(Ang-2 / VEGF))与出现NSCLC的可能性相关(分别为p = 0.016; p = 0.003; p <0.0001)。血清Ang-2和高水平(Ang-2 / VEGF)而非单独的VEGF是独立的预后因素(p = 0.001; p = 0.619; p = 0.005)。高(Ang-2 / VEGF)血清水平可作为NSCLC中新的有价值的整体生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号